TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: intrahepatic disease control rate (iDCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of the ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Acute Gain Index and freedom from clinically driven target lesion revascularization (CD-TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IL-6 and TNF-α levels in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success or failure of sedation maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esthetic properties
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Primary Effectiveness
Endpoint domain: Physiological/clinical
Primary endpoint: prognosis of stroke patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: early neurological changes of ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ECOG-PS assessment of LC participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complications after liver resection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of fecal microbiota transplantation (FMT)-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical response/remission of immune-related diarrhea/colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in sleep spindle density
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants Missing Antibiotic Treatment Round
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Score of Autism Treatment Evaluation Checklist (ATEC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety according to Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Urine Molybdenum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hematology measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum chemistry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic accuracy of perprocedural Holter ECG monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic accuracy of outpatient Holter monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total clinical failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening Rates for Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: macrophage counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in arm reaching movement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in movement smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speed Accuracy Trade-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Subjective Index of Physical and Social Outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cellular rejection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postural Sway (PS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Interference Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Psychosocial Quality of Life Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extrapulmonary clinical manifestations of SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications in PACU
Endpoint domain: Adverse events/effects
Primary endpoint: Eating Attitude Test (EAT-26) questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in histopathological grading of gastric mucosal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biochemical Recurrence-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Cancer resolution on histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of patients qualifying for randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neck pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intracranial progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Safety of intravaginal 5-FU
Endpoint domain: Adverse events/effects
Primary endpoint: Finnish Matrix Sentence Test (FMST)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digits in Noise test (DIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of bleeding recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Muscle strength via resistance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: measure range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Specific Medical abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Multidimensional Students' Life Satisfaction Scale (MSLSS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Euro QoL 5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NIH PROMIS 45
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical performance-Cardiopulmonary fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving fasting glucose <100 mg/dL and/or 2-hour glucose <140 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of T2DM patients achieving HbA1c <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving optimal BP control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Grades 1 and 2 Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Progression of MASLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to confirmed diagnosis of cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthodontic treatment results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage improvement in knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Radiographic Non-Union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of participants discontinuing treatment due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in liver panel parameters: ALT, ALP and AST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Testing completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse reaction and serious adverse reaction evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Monitoring systemic infection
Endpoint domain: Adverse events/effects
Primary endpoint: MDASI-C
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness change of delirium care knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Effectiveness change of delirium care self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness change of delirium critical thinking skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total Clinical Failure Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Liver Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Liver Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With All-cause Mortality and Cause-specific Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants that experienced adverse events, serious adverse events, and unexpected problems
Endpoint domain: Adverse events/effects
Primary endpoint: Total time for booking all patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for Bupropion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero (0) to the Time of the Last Quantifiable Concentration (AUCt) for Bupropion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) for Bupropion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baby Birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baby Gestational Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal Intensive Care (NICU) Utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Timeline Follow-Back
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle mitochondrial respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle mitochondrial reactive oxygen species (ROS) production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle mitochondrial proteome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of responders to therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess weight loss %
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curve reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum HMGB1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Abnormal Maternal Oral Glucose Tolerance Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HOMA-IR Value for Assessing Insulin Resistance in Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Fetal Macrosomia as Measured by Birth Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Intraoperative peak airway pressure (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: True positive/False negative rate for DiffMag system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: True positive/False negative rate for Sentimag system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changing in middle ear pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference in AAQII
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in PANAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in STAI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in PCL
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in BDI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in PTGI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3 years disease free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with grade 2 or greater reactions requiring parenteral rescue medications
Endpoint domain: Adverse events/effects
Primary endpoint: Functional outcome measured by modified Ranking Scale (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difference in PIP cmH20 (Peak inspiratory pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of aspiration risk by quantitative measurements of pepsin and α-amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain with propofol injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall number of stem cells collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titers of anti-VZV neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Dementia Onset
Endpoint domain: Mortality/survival
Primary endpoint: Quality Outcomes Framework (QOF) Recorded Dementia Diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Substance P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of Prostaglandin E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Release of inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CAIT Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Restorations with change of marginal adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit to Stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Disorder Society - Unified Parkinson's Disease Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson's Disease Questionnaire - 39
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Geometric mean titer (GMT) of SARS-CoV-2 serum neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reintegration to Normal Living Index - Modified for Exoskeleton
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PTSD Checklist for DSM-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood lipid measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Graft/Patient survival
Endpoint domain: Mortality/survival
Primary endpoint: glycocalyx components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIVST uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Linkage to PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Linkage to HIV treatment services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Qualitative Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Spinal tracts differentiation and identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: agonist antagonist ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric rating scale (NRS-11)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified oswestry disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total catheterization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in the Brief Psychiatric Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in the Scales for the Assessment of Negative Symptoms (SANS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: adverse remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optimal diagnostic MSOT thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gene expression in candidate genes of the stress signalling pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial flutter burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial tachycardia burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Comfort Level of Wearable Sensors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Safety Level of Wearable Sensors
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Agreement Over Time of Physiological Parameters between Newly-Fabricated Wearable Sensors and Approved Devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the modified Nail Psoriasis Severity Index (mNAPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: atherogenic index of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Montgomery-Asberg Depression Rating Scale (MADRS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychological symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic accuracy for bile duct tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slit-lamp examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Screen Eligible Who Enroll
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Complete the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Withdraw
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent change of cerebral blood flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the Montgomery-Asberg Depression Rating Scale (MADRS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptability as Measured by the System Usability Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Self-Efficacy for Healthy Eating and Physical Activity (SE-HEPA)
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Incidence of HOPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Time to target vessel myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Montgomery Asberg Depression Rating Scale score differences between D0 and W12
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants referred to the Early Diagnostic Response Model (EDRM)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants consented in the Early Diagnostic Response Model (EDRM) study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response rate in the Early Diagnostic Response Model (EDRM) study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants that completed the Early Diagnostic Response Model (EDRM) study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time from referral to completion of the program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bowel, bladder, and sexual dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rates of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes